Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene therapy.

By Bhanvi Satija (Reuters) -The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy Elevidys, a source familiar with the matter told Reuters on Friday.

Sarepta Therapeutics refuses the FDA request to halt its gene therapy shipments following a third patient death, challenging regulatory norms. The controversial Elevidys therapy faces scrutiny while the company deals with financial impacts,